LIXT
Lixte Biotechnology Holdings, Inc.
NASDAQ · Healthcare · Biotechnology · US
$7.21
−6.00%Price chart
Jun 23Jun 26Jul 1Jul 7Jul 10Jul 20Jul 23Jul 28
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−12.0x
Market Cap
$89.28M
MomentumView details →
1D Return
−6.00%
YTD Return
+12.72%
RSI (14)
33.6
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−12.0x
Market Cap
$89.28M
RSI (14)
33.6
MomentumView details →
1D Return
−6.00%
YTD Return
+12.72%
SummaryUpdated Mar 1, 2026
Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) is a clinical-stage drug discovery company founded in 2005 and based in Pasadena, California. The company went public in 2007 and specializes in developing novel therapeutic compounds targeting protein phosphatases, a class of enzymes involved in cellular regulation. Lixte focuses on creating treatments for serious diseases including various cancers, vascular diseases, metabolic disorders, and rare hereditary conditions through its proprietary biomarker technology platform.
Similar companies
Latest newsMore news →
LIXTE Biotechnology Holdings completed its corporate name change to NOMAD Power Solutions, Inc.60d agoLIXTE completed a merger with Nomad Transportable Power Systems.64d agoLIXTE Biotechnology agreed to acquire NOMAD Transportable Power Systems, the market leader in mobile, utility-grade battery energy storage systems.84d ago